Aethlon Medical To Present At International Conference on Dialysis.Business Editors & Health/Medical Writers LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 29, 2003 Aethlon Medical Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AEMD AEMD Automotive Electric Motor Drive (US Department of Energy program) ) announced that it has been invited to make a presentation at the "International Conference on Dialysis V" which starts today at the Fontainebleau Hilton Resort in Miami. Aethlon's Chief Scientific Officer, Dr. Richard Tullis, will present data from recent pre-clinical human blood studies of Aethlon's Hemopurifier(TM) for treating HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome and will discuss market commercialization strategies for this treatment technology. Dr. Tullis will also review opportunities to utilize the Hemopurifier(TM) treatment platform for treating other disease states, including Hepatitis-C. Dr. Tullis is scheduled to give his presentation on Thursday, January 30th at 1:20 p.m. The Renal Research Institute, a joint venture between Fresenius Medical Care Fresenius Medical Care is a German company specializing in the production of medical supplies, primarily to facilitate or aid renal dialysis. It is 37%-owned by the health care company Fresenius SE. , North America and Beth Israel Medical Center Beth Israel Medical Center is a hospital in New York City. It has four major locations providing health services. It acts as University Hospital and Manhattan Campus for the Albert Einstein College of Medicine of Yeshiva University. is hosting the conference. In addition, The American Society of Nephrology (ASN (1) (Autonomous System Number) A unique identifier of an autonomous system on the Internet. Of the 65 thousand ASNs available, more than 30 thousand have been assigned to ISPs and NSPs. ISPs usually have only one ASN, but NSPs may have more than one. ), the International Society of Nephrology (ISN Noun 1. ISN - Switzerland's information network for security and defense studies and for peace and conflict research and for international relations International Relations and Security Network ), the National Kidney Foundation Not to be confused with American Kidney Fund. The National Kidney Foundation, Inc. (NKF) is a major voluntary health organization in the United States. Its mission is to prevent kidney and urinary tract diseases, improve the health and well-being of individuals and (NKF), the Renal Physicians Association (RPA), and the American Nephrology Nursing Association (ANNA) have all endorsed the conference. As in past years, the emphasis of this annual conference is new developments in the field of dialysis. Additional details regarding the conference and The Renal Research Institute can be accessed at www.renalresearch.com. About Aethlon Medical Aethlon Medical develops therapeutic devices that treat HIV/AIDS, Hepatitis-C (HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. ), and other infectious diseases. In pre-clinical testing, Aethlon has published that AEMD-45, its lead product for treating HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. is able to remove 55 percent of HIV from infected human blood in three hours and in excess of 85 percent in 12 hours. Aethlon has also documented that AEMD-45 removes up to 90 percent of toxic viral proteins that deplete immune cells during the equivalent of a one-hour treatment. The AEMD-45 therapeutic device, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method to increase the capability of FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. cleared artificial kidneys (dialysis cartridges) to remove targeted intoxicants from the blood. In the case of AEMD-45, dialysis cartridges are modified to mimic the immune system's response to clear infectious virus from circulation before healthy cells are infected. AEMD-45 is designed to fill the urgent need for new treatments that are effective in reducing viral load, decrease the likelihood of treatment resistance, and treat without the toxic side-effects associated with AIDS drugs. For more information, visit the company's Web site at www.AethlonMedical.com. Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion